Want to see QNRX full AI Analyst Report?
QNRX Stock Chart & Stats
$5.07
-$0.09(-2.06%)
At close: 4:00 PM EDT
$5.07
-$0.09(-2.06%)
Day’s Range― - ―
52-Week Range$3.25 - $41.80
Previous Close$4.1
Volume6.33K
Average Volume (3M)1.11M
Market Cap
$14.58M
Enterprise Value-$1.08
Total Cash (Recent Filing)$10.80M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta-0.99
Next Earnings
Nov 05, 2026EPS Estimate
-1.63Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-14.89
Shares Outstanding2,008,418
10 Day Avg. Volume3,274,428
30 Day Avg. Volume1,106,545
Financial Highlights & Ratios
PEG Ratio0.01
Price to Book (P/B)1.65
Price to Sales (P/S)0.00
P/FCF Ratio-1.60
Enterprise Value/Market Cap>-0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$22.33Price Target Upside340.50% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)-6.52
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Debt-Free Balance SheetThe absence of reported debt limits interest and refinancing pressure, giving Quoin greater flexibility while it advances clinical programs. This does not eliminate funding needs, but it reduces leverage-related downside and preserves more control over future capital allocation.
Extended Funding RunwayThe financing materially improves operating visibility by supplying upfront capital and potentially extending funding into the second half of 2029. A longer runway can support continued QRX003 development and reduce the frequency of near-term financing decisions.
Positive QRX003 Clinical ProgressPositive interim efficacy and safety findings strengthen the case for QRX003 in a severe, ultra-rare disease with no approved therapy. If sustained in later development, this clinical differentiation could support regulatory progress and eventual commercial positioning.
Bears Say
No Revenue And Expanding LossesQuoin remains entirely dependent on development progress rather than commercial revenue, while losses are widening materially. Continued absence of sales limits internal funding capacity and leaves future financial performance dependent on successful clinical and regulatory execution.
Accelerating Cash BurnPersistent and accelerating cash outflows increase the capital required to sustain trials and corporate operations. Even with recent financing, ongoing negative free cash flow means the company must convert pipeline progress into revenue or secure additional funding over time.
Shrinking Equity And AssetsThe sharp decline in equity and total assets reflects cumulative losses and reduces the balance-sheet cushion available to absorb setbacks. It also raises the likelihood that future development will require additional equity capital, creating potential dilution for existing shareholders.
Quoin Pharmaceuticals News
QNRX FAQ
What was Quoin Pharmaceuticals’s price range in the past 12 months?
Quoin Pharmaceuticals lowest stock price was $3.25 and its highest was $41.80 in the past 12 months.
What is Quoin Pharmaceuticals’s market cap?
Quoin Pharmaceuticals’s market cap is $14.58M.
When is Quoin Pharmaceuticals’s upcoming earnings report date?
Quoin Pharmaceuticals’s upcoming earnings report date is Nov 05, 2026 which is in 59 days.
How were Quoin Pharmaceuticals’s earnings last quarter?
Quoin Pharmaceuticals released its earnings results on Aug 14, 2026. The company reported -$1.9 earnings per share for the quarter, missing the consensus estimate of -$1.61 by -$0.29.
Is Quoin Pharmaceuticals overvalued?
According to Wall Street analysts Quoin Pharmaceuticals’s price is currently Undervalued.
Does Quoin Pharmaceuticals pay dividends?
Quoin Pharmaceuticals does not currently pay dividends.
What is Quoin Pharmaceuticals’s EPS estimate?
Quoin Pharmaceuticals’s EPS estimate is -1.63.
How many shares outstanding does Quoin Pharmaceuticals have?
Quoin Pharmaceuticals has 2,008,418 shares outstanding.
What happened to Quoin Pharmaceuticals’s price movement after its last earnings report?
Quoin Pharmaceuticals reported an EPS of -$1.9 in its last earnings report, missing expectations of -$1.61. Following the earnings report the stock price went down -15.868%.
Which hedge fund is a major shareholder of Quoin Pharmaceuticals?
Currently, no hedge funds are holding shares in QNRX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Quoin Pharmaceuticals
Quoin Pharmaceuticals, Ltd. operates as a specialized pharmaceutical firm, concentrating its efforts on devising therapeutic solutions for rare and orphan medical conditions. Its flagship offering, QRX003, is a topical lotion specifically formulated to address Netherton Syndrome. Furthermore, the company is advancing QRX004 for the management of dystrophic epidermolysis bullosa, alongside QRX006, a prospective therapy for an additional rare dermatological ailment. The organization maintains its operational base in Ashburn, Virginia.
QNRX Stock 12 Month Forecast
Average Price Target
$22.33
▲(340.50% Upside)
Technical Analysis
Galmed Pharmaceuticals
―
Jaguar Animal Health
―
Adial Pharmaceuticals
―
Alzamend Neuro
―
Calidi Biotherapeutics
―
Ownership Overview
9.10% Insiders
77.87% Other Institutional Investors
13.03% Public Companies and
Individual Investors